Intuitive's 316,000-Sq-Ft Penang Plant to Boost APAC Surgical Access by 2028

For health system leaders and surgical program directors across Asia Pacific, Intuitive's announced 316,000-square-foot Penang plant is a capacity signal: as robotic-assisted surgery volumes climb, regional instrument availability and service logistics can determine how quickly hospitals scale programs. The facility, due online in 2028, is intended to support the da Vinci ecosystem across 13 markets where the company reports more than 2.5 million patients treated.

Intuitive announced on August 17, 2026 that it has entered into a lease agreement with Penang Development Corporation for a new manufacturing facility in Bandar Cassia Technology Park, Penang, Malaysia. The press release, distributed through PRNewswire and republished by multiple outlets, states the 316,000-square-foot site is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The facility would manufacture surgical instruments and electromechanical devices used with the da Vinci surgical system. Because the information comes from a corporate announcement rather than independent reporting, the timeline and job figures should be treated as company projections.

“

Intuitive announced on August 17, 2026 that it has entered into a lease agreement with Penang Development Corporation for a new manufacturing facility in Bandar Cassia Technology Park, Penang, Malaysia.

The investment is framed as a response to rising demand for robotic-assisted surgery in Asia Pacific. Intuitive says it has operated in the region for more than two decades and that da Vinci systems have enabled surgeons to treat more than 2.5 million patients across 13 markets. Glenn Vavoso, senior vice president and president of Asia Pacific, described the region as one of the most exciting growth opportunities for robotic-assisted surgery. Mark Brosius, executive vice president and chief manufacturing and supply chain officer, said the expansion requires thoughtful, long-term investments to scale while maintaining operational excellence.

From a supply chain perspective, locating instrument and electromechanical device manufacturing in Penang places production closer to APAC customers, which could shorten lead times and reduce logistics costs. Surgical instruments are consumable components within the da Vinci ecosystem; reliable regional availability can influence hospital purchasing decisions, procedure scheduling, and service turnaround. The 2028 start date implies a construction, equipping, and qualification window of roughly two years, during which the company will need to validate cleanroom operations, precision manufacturing processes, and quality systems. No capital expenditure figure or expected capacity in units per year was disclosed in the press release.

Penang is a notable choice because the state has a deep electronics and precision engineering base, along with existing medical technology activity. The 1,200 jobs projected by 2032 are likely to span precision machining, electromechanical assembly, sterilization, quality engineering, and supply chain management. The presence of Penang Development Corporation as landlord and the attendance of Malaysian investment officials at the announcement suggests government support for high-value manufacturing and job creation. For Malaysia, the facility reinforces the country's positioning in the medical device supply chain.

Asia Pacific's minimally invasive surgery market has grown as aging populations, rising chronic disease burden, and healthcare infrastructure investment expand the addressable procedure base. Intuitive's 2.5 million cumulative patients in 13 markets is a lagging indicator of that demand. A regional manufacturing footprint can also be a hedge against tariffs, trade disruptions, and currency volatility, though the press release does not explicitly mention these factors. The plant's focus on instruments and electromechanical devices, rather than full system assembly, suggests a targeted investment in recurring, consumable products that scale with procedure volume.